The etiology of poststroke depression: A review of the literature and a new hypothesis involving inflammatory cytokines

Molecular Psychiatry

Volumn 11, Issue 11, 2006, Pages 984-991

  Spalletta, G ^a,c   Bossu P ^a   Ciaramella, A ^a   Bria, P ^b   Caltagirone, C ^a,c   Robinson, R G ^d  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Cytokines; Depression; Etiology; Inflammatory cytokines; Poststroke depression; Stroke

Indexed keywords

CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1; INTERLEUKIN 18 BINDING PROTEIN; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BRAIN CORTEX; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN REGION; COGNITION; DEPRESSION; HUMAN; MOOD DISORDER; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; STROKE;

ANIMALS; BIOGENIC AMINES; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CYTOKINES; DEPRESSIVE DISORDER; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE;

EID: 33750321709     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001879     Document Type: Article

References (109)

1. Fisher SH. Psychiatric considerations of cerebral vascular disease. Am J Cardiol 1961; 7: 379-385.
2. Meyer A. The anatomical facts and clinical varieties of traumatic insanity. Am J Insanity 1904; 60: 373-442.
3. Robinson RG, Szetela B. Mood change following left hemispheric brain injury. Ann Neurol 1981; 9: 447-453.
4. Starkstein SE, Robinson RG, Price TR. Comparison of cortical and subcortical lesions in the production of post-stroke mood disorders. Brain 1987; 110: 1045-1059.
5. Astrom M, Adolfsson R, Asplund K. Major depression in stroke patients: a 3-year longitudinal study. Stroke 1993; 24: 976-982.
6. Morris PLP, Robinson RG, Raphael B, Hopwood MJ. Lesion location and post-stroke depression. J Neuropsychiatry Clin Neurosci 1996; 8: 399-403.
7. Herrmann M, Bartles C, Wallesch C-W. Depression in acute and chronic aphasia: symptoms, pathoanatomical-clinical correlations and functional implications. J Neurol Neurosurg Psychiatry 1993; 56: 672-678.
8. Herrmann M, Walesch C-W. Depressive changes in stroke patients. Disabil Rehabil 1993; 15: 55-66.
9. Vataja R, Leppavuori A, Pohjasvaara T, Mantyla R, Aronen HJ, Salonen O et al. Post-stroke depression and lesion location revisited. J Neuropsychiatry Clin Neurosci 2004; 16: 156-162.
10. Vataja R, Pohjasvaara T, Leppavuori A, Mantyla R, Aronen HJ, Salonen O et al. Magnetic resonance imaging correlates of depression after ischemic stroke. Arch Gen Psychiatry 2001; 58: 925-931.
11. Bolla-Wilson K, Robinson RG, Starkstein SE, Boston J, Price TR. Lateralization of dementia of depression in stroke patients. Am J Psychiatry 1989; 146: 627-634.
12. Spalletta G, Guida G, De Angelis D, Caltagirone C. Predictors of cognitive level and depression severity are different in patients with left and right hemispheric stroke within the first year of illness. J Neurol 2002; 249: 1541-1551.
13. Spalletta G, Pasini A, Costa A, De Angelis D, Ramundo N, Paolucci S et al. Alexithymic features in stroke: effects of laterality and gender. Psychosom Med 2001; 63: 944-950.
14. Spalletta G, Ripa A, Bria P, Caltagirone C, Robinson RG. Response of emotional unawareness following stroke to antidepressant treatment. Am J Geriatr Psychiatry 2006; 14: 220-227.
15. Bhogal SK, Teasell R, Foley N, Speechley M. Lesion location and post-stroke depression. Systematic review of the methodological limitations in the literature. Stroke 2004; 35: 794-802.
16. Robinson RG, Bloom FE. Pharmacological treatment following experimental cerebral infarction: implications for understanding psychological symptoms of human stroke. Biol Psychiatry 1977; 12: 669-680.
17. Reis DJ, Gilad G, Pickel VM, Joh TH. Reversible changes in the activities and amounts of tyrosine hydroxylase in dopamine neurons of the substantia nigra in response to axonal injury as studied by immunochemical and immunocytochemical methods. Brain Res 1978; 144: 325-342.
18. Bryer JB, Starkstein SE, Votypka V, Parikh RM, Price TR, Robinson RG. Reduction of CSF monoamine metabolites in post-stroke depression. J Neuropsychiatry Clin Neurosci 1992; 4: 440-442.
19. 2-serotonin receptors after stroke: lateralized changes and relationship to depression. Am J Psychiatry 1988; 145: 937-943.
20. Barone FC, Feuerstein GZ. Inflammatory mediator and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19: 819-834.
21. Emsley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, Barberan EM et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003; 139: 93-101.
22. Lindsberg PJ, Grau AJ. Inflammation and infection as risk factors for ischemic stroke. Stroke 2003; 34: 2518-2532.
23. Grundy RI, Rothwell NJ, Allan SM. Site-specific actions of interleukin-1 on excitotoxic cell death in the rat striatum. Brain Res 2002; 926: 142-148.
24. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005; 5: 629-640.
25. Rothwell NJ. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 2003; 17: 152-157.
26. Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 2003; 140: 471-476.
27. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76: 1366-1372.
28. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26: 1393-1398.
29. Kostulas N, Pelidou SH, Kivisakk P, Kostulas V, Link H. Increased IL-1b, IL-8 and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999; 30: 2174-2179.
30. Um YY, Moon KS, Lee KM, Kim HM. Interleukin-1 gene cluster polymorphisms in cerebral infarction. Cytokine 2003; 23: 41-46.
31. Seripa D, Dorbrina A, Margaglione M, Matera MG, Gravina C, Vecile E et al. Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic stroke. Cerebrovasc Dis 2003; 15: 276-281.
32. Lee BC, Ahn SY, Doo HK, Yim SV, Lee HJ, Jin SY et al. Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene. Neurosci Lett 2004; 357: 33-36.
33. Allan SM, Rothwell NH. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001; 10: 734-744.
34. Ferrarese C, Mascaurucci P, Zoia C, Cavarretta R, Frigo M, Begni B et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999; 19: 1004-1009.
35. Kouwenhoven M, Carlstrom C, Ozenci V, Link H. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J Clin Immunol 2001; 21: 365-375.
36. Intiso D, Zarrelli MM, Lagioia G, Di Rienzo F, Checchia De Ambrosio C, Simone P et al. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stoke patients. Neurol Sci 2003; 24: 390-396.
37. Zaremba J, Losy J. Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand 2001; 104: 288-295.
38. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke 1999; 30: 981-985.
39. DiNapoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-924.
40. Arenillas JF, Alvarez-Sabin J, Molina CA, Chaco P, Montaner J, Rovira A et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003; 34: 2463-2468.
41. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol 1995; 37: 800-805.
42. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6 transforming growth factor-beta, and S-100 protein in patients with acute stroke. Stroke 1996; 27: 1553-1557.
43. Vila N, Castillo J, Davalos A, Chamorro A. Pro-inflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-2329.
44. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004; 4: 2.
45. Revilla M, Obach V, Cervera A, Davalos A, Castillo J, Chamorro A. A-174 G/C polymorphism of the interleukin-6 gene in patients with lacunar infarctions. Neurosci Lett 2002; 324: 29-32.
46. Pola R, Fex A, Gaetani E, Flore R, Serricchio M, Pola P. Synergistic effect of -174G/C polymorphism in the interleukin-6 gene promoter and 469E/K polymorphism of the intercellular adhesion molecule-1 gene in Italian patients with history of ischemic stroke. Stroke 2003; 34: 881-885.
47. Acalovschi D, Wiest T, Hartmann M, Farahmi M, Mansmann U, Auffart GU et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 2003; 34: 1864-1869.
48. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S et al. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol 1997; 110: 492-499.
49. Kostulas N, Kivisakk P, Huang Y, Matusevicius D, Kostulas V, Link H. Ischemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke 1998; 29: 462-466.
50. Grau AJ, Aulmann M, Lichy C, Meiser H, Buggle F, Brandt T et al. Increased cytokine release by leucocytes in survivors of stroke at young age. Eur J Clin Invest 2001; 31: 999.
51. Grau AJ, Reis A, Buggle F, Al-Khalaf A, Werle E, Valois N et al. Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. J Neurol Sci 2001; 192: 41-47.
52. Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Buhrer C, Stahel PF. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci 2005; 28: 487-493.
53. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002; 20(5 Suppl 27): S1-S13.
54. Dinarello CA. Interleukin-18, a pro-inflammatory cytokine. Eur Cytokine Netw 2000; 11: 483-486.
55. Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001; 108: 1825-1832.
56. Bossu P, Neumann D, Del Giudice E, Ciaramella A, Gloaguen I, Fantuzzi G et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA 2003; 100: 14181-14186.
57. Culhane AC, Hall MD, Rothwell NJ, Luheshi GN. Cloning of rat brain interleukin-18 cDNA. Mol Psychiatry 1998; 3: 362-366.
58. Conti B, Park LC, Calingasan NY, Kim Y, Kim H, Bae Y et al. Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 1999; 67: 46-52.
59. Wheeler RD, Brough D, Le Feuvre RA, Takeda K, Iwakura Y, Luheshi GN et al. Interleukin-18 induces expression and release of cytokines from murine glial cells: interactions with interleukin-1 beta. J Neurochem 2003; 85: 1412-1420.
60. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-2459.
61. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-1603.
62. Hedtjarn M, Leverin AL, Eriksson K, Blomgren K, Mallard C, Hagberg H. Interleukin-18 involvement in hypoxic-ischemic brain injury. J Neurosci 2002; 22: 5910-5919.
63. Jander S, Schroeter M, Stoll G. Interleukin-18 expression after focal ischemia of the rat brain: association with the late-stage inflammatory response. J Cereb Blood Flow Metab 2002; 22: 62-70.
64. Wheeler RD, Boutin H, Touzani O, Luheshi GN, Takeda K, Rothwell NJ. No role for interleukin-18 in acute murine stroke-induced brain injury. J Cereb Blood Flow Metab 2003; 23: 531-535.
65. Zaremba J, Losy J. Interleukin-18 in acute ischaemic stroke patients. Neurol Sci 2003; 24: 117-124.
66. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol 1995; 37: 800-805.
67. Krupinski J, Kumar P, Kumar S, Kaluza J. Increased expression of TGF-beta 1 in brain tissue after ischemic stroke in humans. Stroke 1996; 27: 852-857.
68. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci 2001; 22: 289-296.
69. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003; 34: 671-675.
70. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4: 317-327.
71. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217.
72. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
73. Bluthe RM, Pawlowski M, Suarez S, Parnet P, Pittman Q, Kelley KW et al. Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology 1994; 19: 197-207.
74. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001; 15: 7-24.
75. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189-1193.
76. Anisman H, Ravindran AV, Griffiths J, Merali Z. Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatry 1999; 46: 1649-1655.
77. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999; 40: 171-176.
78. Owen BM, Eccleston D, Ferrier IN, Young AH. Raised levels of plasma interleukin-1 beta in major and postviral depression. Acta Psychiatr Scand 2001; 103: 226-228.
79. Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composisiton study. Biol Psychiatry 2003; 54: 566-572.
80. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 429-433.
81. Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler M. Inflammatory proteins and depression in the elderly. Epidemiology 2003; 14: 103-107.
82. Maes M, Kenis G, Kubera M. In humans, corticotropin releasing hormone antagonizes some of the negative immunoregulatory effects of serotonin. Neuro Endocrinol Lett 2003; 24: 420-424.
83. Merendino RA, Di Rosa AE, Di Pasquale G, Minciullo PL, Mangraviti C, Costantino A et al. Interleukin-18 and CD30 serum levels in patients with moderate-severe depression. Mediators Inflamm 2002; 11: 265-267.
84. Kokai M, Kashiwamura S, Okamura H, Ohara K, Morita Y. Plasma interleukin-18 levels in patients with psychiatric disorders. J Immunother 2002; 25(Suppl 1): S68-S71.
85. Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Bergmans R, Desnyder R. Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J Affect Disord 1995; 36: 29-36.
86. Kubera M, Kenis G, Bosmans E, Zieba A, Dudek D, Nowak G et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol 2000; 52: 237-241.
87. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol 1995; 41: 534-538.
88. Capuron L, Ravaud A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000; 18: 2143-2151.
89. Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001; 26: 797-808.
90. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45-55.
91. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med 2001; 344: 961-966.
92. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002; 5: 375-388.
93. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999; 79: 1-71.
94. Anisman H, Kokkinidis L, Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 2002; 16: 544-556.
95. Hu B, Hissong BD, Carlin JM. Interleukin-1 enhances indoleamine 2, 3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J Interferon Cytokine Res 1995; 15: 617-624.
96. Fujigaki S, Saito K, Sekikawa K, Tone S, Takikawa O, Fujii H et al. Lipopolysaccharide induction of indoleamine 2, 3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001; 31: 2313-2318.
97. Pemberton LA, Kerr SJ, Smythe G, Brew BJ. Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res 1997; 17: 589-595.
98. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 2000; 12: 588-594.
99. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7: 468-473.
100. Liebau C, Baltzer AW, Schmidt S, Roesel C, Karreman C, Prisack JB et al. Interleukin-12 and interleukin-18 induce indoleamine 2, 3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 2002; 22: 931-936.
101. Jander S, Schroeter M, Stoll G. Interleukin-18 expression after focal ischemia of the rat brain: association with the late-stage inflammatory response. J Cereb Blood Flow Metab 2002; 22: 62-70.
102. Morris PLP, Robinson RG, Andrezejewski P, Samuels J, Price TR. Association of depression with 10-year post-stroke mortality. Am J Psychiatry 1993; 150: 124-129.
103. House A, Knapp P, Bamford J, Vail A. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001; 32: 696-701.
104. Parikh RM, Robinson RG, Lipsey JR, Starkstein SE, Fedoroff JP, Price TR. The impact of post-stroke depression on recovery in activities of daily living over two year follow-up. Arch Neurol 1990; 47: 785-789.
105. Downhill Jr JE, Robinson RG. Longitudinal assessment of depression and cognitive impairment following stroke. J Nerv Ment Dis 1994; 182: 425-431.
106. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002; 16: 569-574.
107. O'Brien SM, Scott LV, Dinan TG. Antidepressant therapy and C-reactive protein levels. Br J Psychiatry 2006; 188: 449-452.
108. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C,Wang A et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
109. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind randomized placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-684.